Why the study?
Does a zotarolimus-eluting stent reduce major cardiac events compared to a paclitaxel-eluting stent in patients with symptomatic coronary artery disease?
Does a zotarolimus-eluting stent reduce major cardiac events compared to a paclitaxel-eluting stent in patients with symptomatic coronary artery disease?
In a real-world registry, zotarolimus-eluting stents were associated with lower rates of myocardial infarction, CABG, and late stent thrombosis at 2 years compared to paclitaxel-eluting stents.
Answers are grounded in this paper and cite their sources.
Zotarolimus-eluting stents were associated with fewer events in this registry; leaves open whether randomized trials will confirm benefit.
BACKGROUND: Our purpose was to investigate the clinical outcomes of Zotarolimus- and Paclitaxel-eluting stents in Turkish patients with coronary artery disease (CAD). In general, the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. However, the difference in efficacy between the Zotarolimus and Paclitaxel-eluting stents in unselected Turkish patients is controversial. Therefore, we investigated the clinical outcomes of these two drug-eluting stents in the real-world. METHODS: We created a registry and prospectively analyzed data on a consecutive series of all patients who presented to our institution with symptomatic coronary artery disease between February 2005 and March 2007 and who were treated with the zotarolimus- or the paclitaxel-eluting stent. The follow-up period was approximately two years. The primary end-point was major cardiac events, and the secondary end-point was definite stent thrombosis. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethical committee. RESULTS: In total, 217 patients were treated with either the zotarolimus-eluting stent (n = 116) or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated similarly by conventional technique. At 24-month follow-up the paclitaxel-eluting stent group showed significantly higher non-Q wave myocardial infarction (2.6% vs 5.9%, p: 0.02), Q wave myocardial infarction (1.7% vs 5.9%, p: 0.049), coronary artery binding graft surgery (2.6% vs 6.9%, p: 0.002), and late stent thrombosis (1.7% vs 3.9%, p: 0.046). CONCLUSIONS: Zotarolimus-eluting stents demonstrated better clinical outcomes than Paclitaxel-eluting stents in a daily routine practice of coronary intervention in an unselected Turkish population.
No takes yet. Share an insight, caveat, or question.
Çiçek et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: